CN112206074B - Tubular vascular-like structure and construction method thereof - Google Patents
Tubular vascular-like structure and construction method thereof Download PDFInfo
- Publication number
- CN112206074B CN112206074B CN201910549415.7A CN201910549415A CN112206074B CN 112206074 B CN112206074 B CN 112206074B CN 201910549415 A CN201910549415 A CN 201910549415A CN 112206074 B CN112206074 B CN 112206074B
- Authority
- CN
- China
- Prior art keywords
- printing
- tubular
- cells
- cell
- winding rod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010276 construction Methods 0.000 title claims abstract description 28
- 238000007639 printing Methods 0.000 claims abstract description 159
- 238000004804 winding Methods 0.000 claims abstract description 78
- 239000007921 spray Substances 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 93
- 108010049003 Fibrinogen Proteins 0.000 claims description 29
- 102000008946 Fibrinogen Human genes 0.000 claims description 29
- 229940012952 fibrinogen Drugs 0.000 claims description 29
- 239000002609 medium Substances 0.000 claims description 21
- 108090000190 Thrombin Proteins 0.000 claims description 20
- 229960004072 thrombin Drugs 0.000 claims description 20
- 230000002792 vascular Effects 0.000 claims description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 11
- 241000283690 Bos taurus Species 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 239000012452 mother liquor Substances 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- 210000002889 endothelial cell Anatomy 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 4
- 239000007640 basal medium Substances 0.000 claims description 3
- 210000003606 umbilical vein Anatomy 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 42
- 238000010146 3D printing Methods 0.000 abstract description 16
- 230000004071 biological effect Effects 0.000 abstract description 16
- 238000001514 detection method Methods 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 8
- 238000004113 cell culture Methods 0.000 abstract description 7
- 210000000056 organ Anatomy 0.000 abstract description 7
- 238000012258 culturing Methods 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 239000012930 cell culture fluid Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 230000001172 regenerating effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 47
- 210000001519 tissue Anatomy 0.000 description 43
- 238000002360 preparation method Methods 0.000 description 22
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 16
- 230000004069 differentiation Effects 0.000 description 15
- 102000009123 Fibrin Human genes 0.000 description 14
- 108010073385 Fibrin Proteins 0.000 description 14
- 229950003499 fibrin Drugs 0.000 description 14
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 13
- 210000000013 bile duct Anatomy 0.000 description 13
- 239000012620 biological material Substances 0.000 description 13
- 108010010803 Gelatin Proteins 0.000 description 12
- 239000008273 gelatin Substances 0.000 description 12
- 229920000159 gelatin Polymers 0.000 description 12
- 235000019322 gelatine Nutrition 0.000 description 12
- 235000011852 gelatine desserts Nutrition 0.000 description 12
- 210000000130 stem cell Anatomy 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 108010023082 activin A Proteins 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 7
- 239000000661 sodium alginate Substances 0.000 description 7
- 235000010413 sodium alginate Nutrition 0.000 description 7
- 229940005550 sodium alginate Drugs 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 6
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000010413 mother solution Substances 0.000 description 6
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 6
- 239000004926 polymethyl methacrylate Substances 0.000 description 6
- -1 polypropylene Polymers 0.000 description 6
- 210000000941 bile Anatomy 0.000 description 5
- 239000013256 coordination polymer Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 229920000747 poly(lactic acid) Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 101710145505 Fiber protein Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 4
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 4
- 108010067787 Proteoglycans Chemical class 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108010059616 Activins Proteins 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 239000000488 activin Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000003754 machining Methods 0.000 description 3
- 210000002220 organoid Anatomy 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229910001256 stainless steel alloy Inorganic materials 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 210000005167 vascular cell Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 2
- 108010022355 Fibroins Proteins 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 2
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 2
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 2
- 101000666775 Homo sapiens T-box transcription factor TBX3 Proteins 0.000 description 2
- 101710123134 Ice-binding protein Proteins 0.000 description 2
- 101710082837 Ice-structuring protein Proteins 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229930182556 Polyacetal Natural products 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001273 Polyhydroxy acid Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 101150106167 SOX9 gene Proteins 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229920000180 alkyd Polymers 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002473 artificial blood Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000009764 endothelial cell sprouting Effects 0.000 description 2
- 239000000246 fibrin derivative Substances 0.000 description 2
- 238000005206 flow analysis Methods 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000000277 pancreatic duct Anatomy 0.000 description 2
- 210000001819 pancreatic juice Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920002721 polycyanoacrylate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920000128 polypyrrole Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 239000003590 rho kinase inhibitor Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102100038409 T-box transcription factor TBX3 Human genes 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003999 epithelial cell of bile duct Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 201000010304 suppurative cholangitis Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2002/043—Bronchi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
- A61F2240/002—Designing or making customized prostheses
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
The invention provides a tubular tissue-like structure and a construction method thereof. The method comprises the following steps: A. preparing printing ink; B. culturing cells for printing in vitro to obtain a cell culture solution; C. and (3) respectively connecting the printing ink and the cell culture fluid with different spray heads of the biological printer, printing the printing ink and the cell culture fluid onto the winding rod together to form a seamless tubular tissue, and removing the winding rod to obtain the hollow tubular tissue-like structure. The method forms a tubular structure with controllable structure and cell/material composition by a horizontal winding type cell 3D printing technology. The tubular structure is similar to the shape and the size of a human body vessel, has mechanical and biological properties required by a human body, has clinical application potential, and can be used for aspects of medicine detection, tissue engineering, regenerative medicine, in-vitro physiological model/pathological model/pharmacological model construction, tissue/organ/human body chip and the like.
Description
Technical Field
The invention relates to the field of biomedical engineering, in particular to a tubular vascular structure and a construction method thereof.
Background
The human body vascular system is widely distributed, and the nutrient substances, oxygen, hormone and the like of various organs in the human body are provided for transportation, thus playing an important role in the growth and development of the whole body tissue organs and maintaining the functions.
The cardiovascular system is the exchange of various organ nutrients with oxygen in the human body. In specific cardiovascular diseases, necrotic blood vessels are sometimes required to be replaced and transplanted, but the existing artificial blood vessels used as operation transplantation still cannot perfectly meet the requirements of high biocompatibility, good mechanical property, systolic and diastolic capacity and the like. For example, the artificial blood vessels with diameters smaller than 6mm currently used for coronary vascular grafting still have the problem of low patency, and at the same time, the customization and manufacturing of vascular structures with complex shapes are difficult at present. Thus, vascular construction has also been a common problem in biological tissue and organs.
The bile duct of human body mainly acts to convey bile secreted by liver cells to duodenum, helping digestion of fatty foods. Bile duct blockage causes cholestasis, which can cause acute obstructive suppurative cholangitis, which can endanger life. At this time, the use of bioengineered bile ducts may be an alternative to liver transplantation. Thus, there is a great need for bioengineered bile ducts that feature the structure, structural characteristics, markers and functions of the bile ducts of the human body (alkaline phosphatase and gamma-glutamyltransferase activity).
The human trachea is used as a pipeline for connecting the throat and the bronchus, is not only an air channel, but also has the functions of defending, removing foreign matters and regulating the temperature and the humidity of the air. Throat and trachea stenosis or defect is a disabling disease which seriously affects the life quality of people. Excision of the lesion is often required, and healing problems after excision are a major clinical problem. And constructing a bioengineered trachea with tracheal structural features and functions may be critical to solving this problem.
The pancreatic duct of the human body drains pancreatic juice to the duodenum to help digest food. The pancreatic duct is blocked to cause the poor drainage of pancreatic juice, and can induce acute pancreatitis. In addition, the human body has other ductal organoids such as ureters, lymphatic vessels, intestinal tracts, etc., which once diseased, can severely affect the health of the body. The use of tubular biological structures for in vitro transplantation has become a common method. Therefore, the construction of tubular tissue with a certain combination of mechanical properties and biological properties becomes a great clinical requirement and is also a research focus of tissue engineering.
Biological 3D printing is defined as using active cell-containing material for 3D printing techniques. The biological printing technology can arrange a large number of active cells and active biological materials at pre-designed spatial positions according to a bionic principle and a computer design, and has great advantages in construction of various tissues and organs of a human body. However, printing a tubular tissue with a personalized structure size (diameter, thickness, length, curvature, etc.) and corresponding mechanical and biological properties, etc. to meet clinical requirements is still a problem to be solved. Thus, for more complex in vitro tissues, particularly longer tubular structures, such as blood vessels, trachea, bile ducts, throats, etc., there is a need to develop new cell printing processes. The method realizes the separate control and controllable delivery of various materials and the stable manufacture of a longer tubular structure.
Disclosure of Invention
The invention aims to provide a tubular tissue-like structure and a construction method thereof.
The invention is characterized in that: the mixing and the conveying of substances such as biological ink, cross-linking agent, active cells and the like are controlled by adopting a horizontal winding type cell 3D printing technology. The rod-shaped collecting device which rotates slowly is used as a forming platform, a horizontal winding mode of printing ink is constructed, and a hollow tubular tissue-like structure body with a longer length is formed.
In order to achieve the object of the present invention, in a first aspect, the present invention provides a method for constructing a tubular tissue-like structure, comprising the steps of:
A. preparing printing ink;
B. culturing cells for printing in vitro to obtain a cell culture solution;
C. and (3) respectively connecting the printing ink and the cell culture fluid with different spray heads of the biological printer, printing the printing ink and the cell culture fluid onto the winding rod together to form a seamless tubular tissue, and removing the winding rod to obtain the hollow tubular tissue-like structure.
The material of the printing ink is a temperature sensitive material and/or a biological material with good cell compatibility and biocompatibility; the biological material adopts one or more natural biological materials and/or artificial synthetic biological materials.
The natural biological material is selected from gelatin, gelatin derivatives, alginate derivatives, cellulose-derived materials, agar, matrigel, collagen derivatives, amino acids, amino acid derivatives, proteoglycans, proteoglycan derivatives, and combinations thereof at least one of glycoprotein and derivative material, hyaluronic acid derivative, chitosan derivative, DNA hydrogel material, laminin, fibronectin, fibrin, silk fibroin derivative, etc. Fibrin derivatives are preferred.
The synthetic biomaterial is at least one selected from polypropylene, polystyrene, polyacrylamide, polylactide, polyglycolide, polylactic acid-glycolic acid copolymer, polyhydroxyacid, polylactic acid-alkyd copolymer, polydimethylsiloxane, polyanhydride, polyacrylate, polyamide, polyamino acid, polyacetal, polycyanoacrylate, polyurethane, polypyrrole, polyester, polymethacrylate, polyethylene, polycarbonate, polyethylene oxide and the like. Polylactic acid or lactic acid-glycolic acid copolymer is preferred.
The cells in the step B may be vascular cells selected from at least one of vascular endothelial cells, vascular endothelial progenitor cells, microvascular endothelial cells, vascular smooth muscle cells, vascular fibroblasts, mesenchymal stem cells, pericytes, and the like. Vascular endothelial cells and mesenchymal stem cells are preferred.
Wherein the vascular cells are extracted from a tissue or are differentiated from stem cells.
The winding rod used in the foregoing method may be a glass rod.
Preferably, the distance between the spray head and the winding rod is 3-4mm.
The rotation speed of the motor driver for driving the winding rod to rotate is 0-10000cts/s, and the rotation speed of the motor driver for driving the printing spray head to translate is 0-10000cts/s.
In a second aspect, the present invention provides a tubular tissue-like structure constructed according to the above method.
The tubular tissue-like structure provided by the invention can be used for constructing a three-dimensional in-vitro biological model of a tubular structure, and performing physiological and pathological analysis and research and in-vitro drug testing.
In a third aspect, the present invention provides a method for constructing a tubular vascular-like structure, comprising the steps of:
1) 0.02g of bovine fibrinogen (MACHLIN, F823833-1 g) was dissolved in 500. Mu.l of DMEM/F-12 HEPES (MACHLIN, F6519-500 ml) medium to obtain a fibrinogen solution;
2) Human umbilical vein endothelial cells HUVEC were treated with EBM-2 Endotheslial Growth Basal Medium (LONZA, CC-3156) in vitro and passaged, cultured until the fourth generation before printing, cells were rinsed with PBS, then Trypsin-EDTA (Sigma, 59417C-500 ML) was added to the flask, digested for 2 minutes in a 37℃incubator, and then EBM (LONZA, CC-3156) broth was added to terminate the digestion; centrifuging in a centrifuge, removing supernatant, re-suspending cells with culture solution, counting, centrifuging again, removing supernatant, and adding fibrinogen solution of step 1) to cell sediment to obtain 4×10 6 cell/ml of a cell-containing fibrinogen solution as printing reagent 1;
3) Preparing 20U/ml thrombin mother liquor (bovine thrombin) by using DMEM/F-12HEPES (MACHLIN, F6519-500 ml) culture solution; before printing, 500 μl of thrombin mother liquor was added to 0.12g of anhydrous calcium chloride (alternatively glutaraldehyde, carbodiimide or glycine), dissolved and incubated in a 37 ℃ incubator for 5 minutes to obtain printing reagent 2;
4) And (3) respectively connecting the printing reagents 1 and 2 with different spray heads of the biological printer, printing on a winding rod together to form a seamless tubular tissue, and removing the winding rod to obtain the hollow tubular vascular-like structure.
Wherein, in the step 4), the distance between the spray head and the winding rod is 3-4mm.
The motor-driven drive that rotates the winding bar rotates at a speed of 0-10000cts/s (preferably 100cts/s, i.e., 100 seconds of one revolution), while the motor-driven drive that translates the print head rotates at a speed of 0-10000cts/s (preferably 80cts/s, i.e., 125 seconds of one revolution).
In a fourth aspect, the present invention provides a method for constructing a tubular bile duct-like structure, comprising the steps of:
1) 0.02g of bovine fibrinogen was dissolved in 500. Mu.l of DMEM/F-12HEPES (MACHLIN, F6519-500 ml) medium to obtain a fibrinogen solution;
2) Preparation of printing reagent 1:
(1) hPSCs cells (human multifunctional stem cells) culture: a proper amount of hPSCs (Stemcell, 5795) is taken for resuscitating culture, and the culture solution is as follows: acivin A100ng/ml, bFGF 80ng/ml, BMP-4 10ng/ml, LY294002 10. Mu.M and CHIR99021 3. Mu.M were cultured overnight at 37 ℃;
(2) differentiation culture of hPSCs into DE (definitive endoderm) cells: the following day, the culture broth of (1) was replaced with CDM-PVA culture broth supplemented with activin A (Abcam, ab 113316) 100ng/ml, bFGF (Beyotime, P6443-100. Mu.g) 80ng/ml, BMP-4 10 (Sigma, RAB0030-1 KT) ng/ml and LY294002 (CST, 9901S) 10. Mu.M, and cultured overnight at 37 ℃; on the third day, the old broth was replaced with RPMI/B27 broth supplemented with activin A (Abcam, ab 113316) 100ng/ml and bFGF (Beyotime, P6443-100. Mu.g) 80 ng/ml;
(3) differentiation of DE cells into FP cells (foregut progenitor cells): on days 4-6, old broth was replaced with RPMI (MACHLIN, R6516-500 ml)/B27 (Sigma, SCM 013) broth supplemented with activin A (Abcam, ab 113316) 50 ng/ml; on days 7-8, the old culture medium was replaced with RPMI/B27 medium supplemented with activin A50 ng/ml;
(4) differentiation of FP cells into HB cells (hepatoblasts): on days 9-12, the old broth was replaced with RPMI/B27 broth containing SB-431542 (Sigma, S4317-5 MG) 10. Mu.M and BMP-4 (Sigma, RAB0030-1 KT) 50 ng/ml; detecting differentiation of HB cells by measuring expression of HNF4A, AFP and TBX3 genes and flow analysis;
(5) Differentiation of HB cells into CP (biliary epithelial progenitor cells): on days 13-16, the differentiation of CP cells was examined by measuring the expression of Sox9 gene by replacing old culture broth with RPMI/B27 broth containing FGF10 (DLDEVELOP, DL-FGF 10-Hu) 50ng/ml, activin A50ng/ml and retinoid acid (Beyotime, AF 2398) 3. Mu.M;
(6) washing CP cells with PBS, adding cell digestive juice, incubating for 20 minutes in a 37 ℃ incubator, and collecting cells with a pipette; transferring the cells to RPMI/B27 medium, resuspending the cells, centrifuging at room temperature for 3 min, discarding the supernatant, resuspending the cells in 50% Matrigel matrix gel (BD, XYHZ-267) containing EGF (peprotech, AF-100-15-100) 20ng/ml and Rho kinase inhibitor Y-2763210 μm, centrifuging again after counting, discarding the supernatant, adding the fibrinogen solution of step 1) to the cell pellet to obtain 4X 10 6 cell/ml of a cell-containing fibrinogen solution as printing reagent 1;
3) Preparing 20U/ml thrombin mother liquor (bovine thrombin) by DMEM/F-12HEPES culture solution; before printing, 500 μl of thrombin mother liquor was added to 0.12g of anhydrous calcium chloride (alternatively glutaraldehyde, carbodiimide or glycine), dissolved and incubated in a 37 ℃ incubator for 5 minutes to obtain printing reagent 2;
4) Printing reagents 1 and 2 respectively connected with different spray heads of a biological printer, printing onto a winding rod together to form a seamless tubular tissue, and removing the winding rod to obtain a hollow tubular three-dimensional structure;
5) The tubular three-dimensional structure of step 4) was placed in WE (Sigma, W2895-1 MG) culture solution containing EGF 20ng/ml, the medium was changed every 2 days, and after culturing for 2-4 days, a tubular bile duct-like structure was formed.
Wherein, in the step 4), the distance between the spray head and the winding rod is 3-4mm.
The motor-driven drive that rotates the winding bar rotates at a speed of 0-10000cts/s (preferably 100cts/s, i.e., 100 seconds of one revolution), while the motor-driven drive that translates the print head rotates at a speed of 0-10000cts/s (preferably 80cts/s, i.e., 125 seconds of one revolution).
In the present invention, the fibrin hydrogel may be obtained by reacting fibrinogen with thrombin, and belongs to an enzyme-crosslinked hydrogel. The specific mechanism is as follows: thrombin, when mixed with fibrinogen, will cleave off two polypeptides at the ends of the alpha and beta chains on fibrinogen to form fibrin monomers, which spontaneously crosslink to form fibrin hydrogels due to hydrogen bonding.
Other systems such as fibrin and gelatin mixtures, alginic acid and collagen mixtures, and the like may be used in the present invention to replace the fibrinogen-thrombin-calcium chloride system described above.
In a fifth aspect, the present invention provides a method for constructing a tubular bronchial-like structure, comprising the steps of:
1) Preparation of printing ink
Gelatin (Sigma-Aldrich, G1890) and sodium alginate (Sigma-Aldrich, A0682) were dissolved in 0.5% w/v sodium chloride solution, respectively, to form a 15% gelatin solution and a 4% sodium alginate solution; mixing 600 mu L of gelatin solution and 400 mu L of sodium alginate solution, and preserving the temperature of the obtained mixed solution at 37 ℃ for 20 minutes to obtain printing ink;
2) Preparation of printing cells
Culturing human lung bronchial epithelial cells and human fetal lung fibroblasts, respectively, using H-DMEM medium (Hyclone, SH 30022.01) containing 10% FBS; when the cell grows and spreads on 80% -90% of the bottom of the dish, the cell is digested by enzyme liquid containing 0.04% EDTA and 0.25% pancreatin (TargetMol, T0517-50 mg), and the cell is passaged according to the proportion of 1:6, and the culture solution is replaced every other day; culturing until the fourth generation before printing; then, the human lung bronchial epithelial cells and the human fetal lung fibroblasts were mixed in a ratio of 5:1 to obtain a cell density of 6×10 5 Cell culture broth per ml;
3) And (3) connecting the printing ink of the 1) and the respective cell culture solution of the 2) with different spray heads of a biological printer, printing the printing ink and the respective cell culture solution onto a winding rod together to form a seamless tubular tissue, and removing the winding rod to obtain the hollow tubular bronchus-like structure.
Wherein, in the step 3), the distance between the spray head and the winding rod is 3-4mm.
The motor-driven drive that rotates the winding bar rotates at a speed of 0-10000cts/s (preferably 100cts/s, i.e., 100 seconds of one revolution), while the motor-driven drive that translates the print head rotates at a speed of 0-10000cts/s (preferably 80cts/s, i.e., 125 seconds of one revolution).
The invention provides a tubular tissue-like structure and a construction method thereof. The method forms a tubular structure with controllable structure and cell/material composition by a horizontal winding type cell 3D printing technology. The tubular structure is similar to the shape and the size of a human body vascular, has mechanical and biological properties required by the human body, and has clinical application potential. The tubular tissue-like structure provided by the invention can be used for aspects such as drug detection, tissue engineering, regenerative medicine, in-vitro physiological model/pathological model/pharmacological model construction, cell structure construction, organoid construction, tissue/organ/human body chip and the like.
By means of the technical scheme, the invention has at least the following advantages and beneficial effects:
the core components of the invention are the 3D printing nozzle and the winding rod, the printing nozzle is flexible in design and various in printing modes. The utilization rate of the printing material is improved, and the configuration requirement of the printing material is reduced. The application range and the combination possibility of the printable material are expanded, so that the method has wide applicability and is beneficial to constructing the printing material with more complex structure and function.
The tubular tissue can be applied to the replacement and bypass operation of various vascular system lesion parts of human bodies, and has biocompatibility.
The tubular tissue can be produced in batches, the construction difficulty of the tubular structure can be reduced, the construction time can be shortened, the construction cost of the tubular tissue can be reduced, and more patients can receive tubular disease treatment by improving the printing platform.
The tubular tissue can be personalized, and the tubular tissue suitable for different types of pulse systems of human bodies is constructed by allocating and printing ink proportion and cell types according to requirements.
And fifthly, the cells used by the tubular tissue can be autologous cells so as to construct a tubular structure which can adapt to the physiological environment of a human body and has no immune rejection reaction, and is more suitable for repairing the pathological change part of the vascular system of the human body.
In the construction of the tubular tissue, the shape and the size of the winding rod can be changed by changing the operation mode of the printing spray head, and the tubular tissue with personalized structure size (diameter, thickness, length, curvature, bifurcation and the like) can be constructed.
The tubular tissue constructed by the invention can be constructed by changing the proportion of printing materials, so that the tubular tissue with directional or staggered protein fiber arrangement can have mechanical properties close to human tissue.
According to the invention, the tubular structure is constructed by combining the 3D printing spray head translation mode with the winding rod unit rotation mode, and the method has the advantages of simple module construction, convenient assembly, detachability, reusability and better operability.
The invention adopts the winding rod unit to construct the tubular structure, wherein the winding rod unit can be a tubular structure with certain mechanical property and biological property, so as to construct the composite tubular structure with multilayer structure, mechanical property and biological property.
Drawings
FIG. 1 is a flow chart of a cell printing method according to the present invention.
FIG. 2 shows the structure of the cell-bearing structure of example 1 after printing immersed in the culture solution.
FIG. 3 is an optical microscope image of a tubular tissue-like structure Day 6 constructed in example 1 of the present invention.
FIG. 4 is a staining chart of a tubular tissue-like structure CD31 constructed in example 1 of the present invention, and a schematic view of a three-dimensional reconstruction of a Confocal layer scan.
FIG. 5 is a statistical result of the sprouting of endothelial cells in printed structures according to example 1 of the present invention. The graph shows the length of budding of cells per unit area for different times of culture.
FIG. 6 is a CK19 immunostaining pattern of biliary epithelial progenitor cells in the tubular bile duct-like structure of example 2 of the present invention.
Detailed Description
The following examples are illustrative of the invention and are not intended to limit the scope of the invention. Unless otherwise indicated, the technical means used in the examples are conventional means well known to those skilled in the art, and all raw materials used are commercially available.
The invention utilizes the 3D printing nozzle to accurately control trace substances and crosslinking parameters and the horizontal rotary winding type receiving device to complete the cell three-dimensional printing technology for instantly printing and constructing the tubular structure.
As shown in fig. 1, the three-dimensional cell printing method for constructing a tubular structure of the present invention comprises the steps of:
1) Preparation of printing platform
The tubular structure constructed by the present invention is primarily dependent on the construction of the winding type printing apparatus. The design of the winding type printing equipment is mainly divided into two aspects, namely a winding rod capable of performing accurate rotation and a printing spray head capable of accurately translating, wherein the translation direction of the printing spray head is parallel to the winding rod and is positioned in the same vertical direction. Meanwhile, the winding rod and the printing nozzle are controlled by an independent motor driving system, so that the speed of the winding rod and the speed of the printing nozzle are independent and adjustable.
2) Preparation of printing ink (biological printing material, printing substrate)
Printing ink is prepared, and an ink distribution scheme (e.g., composition, volume ratio, etc., but not limited thereto) is set. Cells for printing are prepared. The printing nozzle is driven by a power driving system (pneumatic mode but not limited to the method) to spray printing ink.
3) Print parameter setting
And starting a printing mode and controlling a printing process. According to the size (diameter, thickness and length) of the printing tubular tissue structure, the jet speed of printing ink in the 3D printing nozzle is set, the running speed of the winding rod is set, and the translational running speed of the printing nozzle is set. The printing ink in the 3D printing nozzle is pushed out through the nozzle, and begins to adhere to the winding rod under the action of gravity. At the same time, the winding rod rotates in real time, whereby the threadlike mixture extruded by the spray head starts to wind along the winding rod. Meanwhile, the translation of the printing spray head and the rotation of the winding rod are combined to finish the printing of the tubular structure tissue with the specific size.
4) Print product detection and parameter correction
And taking down the tubular structure formed by preliminary printing, and detecting the form and the structural size of the tubular structure. The printing parameters are corrected against their differences from the target tubular structure. Repeating the steps 1-4, and printing again.
5) Printing finished product culture
By controlling the printing time, a complete tubular structure of a corresponding length is printed. The whole tubular tissue is placed in a culture medium for long-term dynamic culture.
6) Detecting physical and chemical properties and biological properties of tubular tissue
After the tubular tissue is cultured in the culture solution for a period of time, the tubular tissue is taken out for detection of mechanical properties and biological properties.
In a preferred embodiment, the printing platform in the step 1) may adopt various construction forms, such as a frame type, a suspended ceiling type and other assembly construction forms, so as to form a printing platform with stable overall structure and convenient operation, so as to ensure stable printing process and reduce printing errors.
In a preferred embodiment, the 3D printing head in the step 1) may take the form of a plurality of types of heads, such as a single-axis hollow head, a duplex hollow head, and a microfluidic chip head based on the microfluidic principle
In a preferred embodiment, the printing heads in step 1) may be arranged in a plurality of numbers to complete the printing of both single-layer and multi-layer tubular structures.
In a preferred embodiment, the winding rod in the step 1) may be changed to a clamping mode having a certain inclination angle with respect to the horizontal direction, so as to print a tubular structure with a gradually changed thickness.
In a preferred embodiment, the winding rod in the step 1) can be replaced by a lumen structure body with a certain structural strength and biological activity through tissue engineering culture in advance, so as to construct a composite tubular tissue-like structure body with multi-level biological characteristics.
In a preferred embodiment, the winding rod in the step 1) can be sleeved in the lumen structure to construct a composite tubular tissue-like structure with a multilayer lumen structure.
In a preferred embodiment, the movement of the printing head and the winding rod in the step 1) may be combined, so that the printing head translates, and the winding rod rotates fixedly. Or the printing nozzle is fixed, and the winding rod rotates to advance. Or both travel simultaneously, completing printing of the tubular structure.
In a preferred embodiment, the printing head in step 1) may be configured to reciprocate to perform printing of both single-layer and multi-layer tubular structures.
In a preferred embodiment, the rotational movement of the winding rod in step 1) may change the rotational direction of the winding rod or set the rotational direction to alternate with time to construct a tubular tissue having different fiber arrangement patterns or non-uniform thickness.
In a preferred embodiment, the rotational speed of the winding rod in the step 1) can be adjusted by self, and the translational speed of the printing nozzle can be adjusted by self. The two speeds can be combined independently to realize the printing of tubular structures with different structures and sizes.
In a preferred embodiment, the rotational speed of the winding rod and the translational speed of the printing head in the step 1) can be adjusted by self. The adjusting mode can be realized by controlling the working state of the driving motor or increasing the speed conversion joint.
In a preferred embodiment, the step 1), the printing nozzle may use three-dimensional drawing software (such as, but not limited to, solidworks) to design a three-dimensional structure of the 3D printing nozzle; the molding is performed by processing (such as molding, but not limited to) using a conventional material (such as PDMS, PMMA, but not limited to).
In a preferred embodiment, the winding rod in step 1) may be one or more of glass, resin, etc. The cross-sectional configuration may be one or more of circular, elliptical, or polygonal. The diameter may be a single diameter or vary with the direction of the axis. The center line of the device can be a straight line, a curve or the like. By means of different settings of the winding bars, printing of tubular structures of different configurations is accomplished.
In a preferred embodiment, the printing ink material in the step 2) is a mixture of temperature sensitive material and/or other biological material with good cell compatibility and biocompatibility; wherein the biological material may be one or more natural biological materials and/or artificial synthetic biological materials.
In some embodiments, the natural biological material used in the printing ink in step 2) is at least one of the following materials: gelatin, gelatin derivatives, alginates (e.g., sodium alginate), alginate derivatives, cellulose-derived materials, agar, matrigel, collagen derivatives, amino acids, amino acid derivatives, proteoglycans, proteoglycan derivatives, glycoproteins and derived materials, hyaluronic acid derivatives, chitosan derivatives, DNA hydrogel materials, laminin, fibronectin, fibrin, silk fibroin derivatives, more preferably fibrin derivatives.
In some embodiments, the synthetic biomaterial used in the printing ink in step 2) is at least one of the following materials: polypropylene, polystyrene, polyacrylamide, polylactide, polyglycolide, polylactic acid-glycolic acid copolymer, polyhydroxyacid, polylactic acid alkyd copolymer, polydimethylsiloxane, polyanhydride, polyacrylate, polyamide, polyamino acid, polyacetal, polycyanoacrylate, polyurethane, polypyrrole, polyester, polymethacrylate, polyethylene, polycarbonate, polyethylene oxide, preferably polylactic acid or lactic acid-glycolic acid copolymer.
In some embodiments, the vascular cells used in the printing ink in the step 2) include vascular endothelial cells, vascular endothelial progenitor cells, microvascular endothelial cells, vascular smooth muscle cells, vascular fibroblasts, mesenchymal stem cells and pericytes, which may be extracted from tissues or differentiated from stem cells, preferably vascular endothelial cells and mesenchymal stem cells.
In a preferred embodiment, in the step 3), the printing ink may be reacted (cross-linked reaction, but not limited thereto) before, during and after the pushing action of the printing head to form filament polymers for winding, so as to complete the tubular structure with the fiber structure.
In some embodiments, the physical and chemical properties and biological properties in the step 6) may be measured by using experimental methods such as (uniaxial tensile test, immunofluorescence test, but not limited thereto).
In a preferred embodiment (example 1), the medium used for tubular tissue culture is a medium that maintains one or more tissue configurations fixed, stable and structurally or functionally enhanced, as shown in FIG. 2.
In a preferred embodiment (embodiment 1), as shown in fig. 4, for detecting the morphology and the size structure of the tubular tissue, detection means such as (but not limited to) an optical microscope and a scanning electron microscope may be used.
EXAMPLE 1 construction of fibrin tubular vascular-like Structure
1. Print platform preparation
The stainless steel alloy frame structure is constructed, the 3D printing spray head and the winding rod are assembled in the frame, the motor control system is debugged, the motion system is constructed, the 3D printing spray head can perform translational motion, and the winding rod can perform rotational motion. In the installation, guarantee that 3D prints the shower nozzle and settles directly over the winding stick, be located same vertical plane with the winding stick. The winding rod is horizontally arranged, the rotation movement of the winding rod can be accurately controlled, and the translation direction of the 3D printing spray head is along the axial direction of the winding rod, and the movement of the winding rod can also be accurately controlled. The platform structural parts are customized from enterprises, few parts such as motor mounting plates and the like are obtained by purchasing raw materials such as plates, drawing the design by itself and entrusting professional machining units to process.
The embodiment adopts a microfluidic chip nozzle based on the microfluidic principle, and designs a structure diagram of the microfluidic chip by using Solidworks structural design software. The micro-fluidic flow channel adopts Y+S shape, on one hand, in order to increase the path travelled by the mixed liquid, more change space is reserved for the pushing speed, and on the other hand, the S-shaped channel is also beneficial to the uniform mixing of the mixed liquid. Rounded corners are arranged at the converging inlets of the mixing channels, so that bubbles are prevented from being generated at the converging inlets due to sharp corners when liquid flows. In order to avoid influencing the printing performance of the material, hydrophilic materials or coatings are selected on the surfaces of the spray nozzle materials or the channels so as to reduce the adsorption of fibrin gel and avoid the problem of channel blockage.
In the embodiment, a detachable PMMA chip printing nozzle is designed, a layer of pressure-sensitive adhesive is clamped between two PMMA chips, and the PMMA chips are fixed by using screws. Meanwhile, a plastic joint is used, a rubber seal steel needle is used as a guide, and a PVC pipe is used as an injection pipe, so that the PVC pipe has a smoother surface and can effectively avoid liquid seepage.
The winding rod used for the winding type rotary motion is a glass rod with a certain length and diameter.
2. Printing ink (biological printing material) preparation
The printing ink can be purchased through commercial paths and can also be prepared according to actual needs, the printing material (printing ink) is prepared before the fibrin tubular vascular structure is printed, and the specific preparation process is as follows:
1) Preparation of printing ink for Main Material (bovine fibrinogen and thrombin)
The bovine fibrinogen needs to be stored in a refrigerator at the temperature of minus 20 ℃ for a long time, and is prepared at present, when the bovine fibrinogen is prepared, a weighing balance is sprayed with alcohol and then is carried into an ultra-clean bench, ultraviolet light is used for irradiation sterilization for 30 minutes, 0.02g of powder is mainly used for printing each time, and a tube containing 0.02g of fibrinogen is taken out each time and dissolved in 500 mu l of DMEM/F-12HEPES culture solution, so that the DMEM in the culture solution is ensured to be completely dissolved without precipitation.
The thrombin is firstly split-packed into a plurality of EP tubes by PBS, each tube contains 100U and is stored at the temperature of minus 20 ℃, only one tube is needed to be taken out for preparing a batch of materials, and the same DMEM/F-12HEPES culture solution is used for diluting into a total mother solution of 20U/ml and 5ml, the mother solution is wrapped with tinfoil and is stored in a refrigerator at the temperature of 4 ℃ in a dark place, and one batch of mother solution is printed for a plurality of times. For each printing, a new EP tube was first filled with a single particle of anhydrous calcium chloride having a mass of about 0.12g, and 500. Mu.l of thrombin mother liquor was added for blowing until complete dissolution, and the solution was placed in a 37℃incubator for 5 minutes after completion of the preparation.
The final concentrations used in this example were 20mg/ml fibrinogen, 10U/ml thrombin, 120mM calcium chloride, and 1ml syringe was used to aspirate the material prior to printing, taking care to minimize aspiration bubbles, and the syringe was tapped after aspiration to eliminate bubbles.
2) Preparation of cells in printing ink
The cells used in the printing of this example were human umbilical vein endothelial cells HUVEC, were cultured using EBM-2 Endothelial Growth Basal Medium (Lonza) and the number of preprinted generations was fourth generation, and prior to printing, the T75 flask was rinsed with PBS and 3ml of 0Digesting 25% Trypsin-EDTA (Thermal Fisher) in a 37 deg.C incubator for 2 min, adding 6 ml EBM culture solution to stop digestion, centrifuging at 1000rpm for 3 min, taking out supernatant, adding 1ml culture solution to resuspend cells, counting with cell counting plate to obtain cell concentration and estimating total cell number, centrifuging again, removing supernatant, adding 500 μl fibrinogen solution to obtain 4×10 6 cell/ml of fibrinogen solution containing cells.
3. Print settings
All transfusion works in the printing process are mainly finished by using a baoding Shen Chen SPLab02 injection pump, before each printing, the flow channel is perfused by deionized water, and 50 mu l of the flow channel is flushed at a flow rate of 5 mu l/min. After the washing is finished, the chips are respectively connected with the fibrinogen and thrombin tubes and are filled with liquid, the total amount is generally set to 400 mu l at 5 mu l/min, a fast forward key on a syringe pump can be used in a small amount to enable the inside of the flow channel to reach a steady state rapidly, when pink liquid bead gel appears below the chips, a printer beam on a microfluidic chip spray head frame can be seen, and the distance between a spray head and a glass tube for winding is about 3-4mm.
And the printer parameter part adjusts the rotation speed of the winding rod to be 100cts/s, namely 100 seconds, and the rotation speed of a motor driver driving the printing nozzle to translate is 80cts/s, namely 125 seconds, so that the tubular tissue without gaps can be stably printed. The tubular vascular structure with the total length of 6cm and the wall thickness of 2mm can be printed at one time.
4. Print product detection and parameter correction
And (3) using an optical microscope and an electronic scanning microscope to observe and detect the printed tubular structure, correcting printing parameters (the rotation rate of a winding rod, the injection rate and the translation speed of a microfluidic chip nozzle and the like), and printing again.
5. Printing finished product culture
The printed fibrin hollow structure was placed in a culture dish rich in culture medium.
6. Vascularization detection of physical and chemical properties and biological properties of tubular tissue
After the hollow fiber protein structure is cultured in the culture solution for a period of time, the hollow fiber protein structure is taken out for detection of mechanical properties and biological properties. The mechanical properties of the fibrin hollow structure body are measured and calculated by applying a uniaxial tension test, and compared with the vascular characteristics of a human body. The cell survival status was examined using CCK8 cell proliferation, and the cell proliferation growth status was examined using immunofluorescence assay (CD 31 and DAPI).
FIG. 3 is a light microscope image of a tubular tissue-like structure Day 6 constructed in this example. Figure 4 shows that endothelial cells spread well in the printed oriented fibrin and form a choroidal structure. FIG. 5 is a statistical result of endothelial cell sprouting in printed structures, showing that the endothelial cell sprouting length increases with increasing culture time, indicating that vascularization begins inside the tubular structures.
EXAMPLE 2 construction of a fibrin tubular bile duct-like Structure
1. Print platform preparation
The printing platform with the stainless steel alloy frame structure mainly comprises a printing nozzle and a winding unit for tubular construction. The printing platform and the components thereof are designed in an autonomous drawing mode, and each component can be processed through enterprise customization or entrusting professional machining units.
The micro-fluidic chip spray head designed based on the micro-fluidic principle is applied to the embodiment, and PMMA material is applied to construct the micro-fluidic chip spray head with Y+S configuration flow channels. The spray head can effectively promote solution fusion and can prevent the problem of channel blockage.
The diameter of the glass tube for winding used in this example was about 0.5cm, which is similar to the diameter of the bile duct of the human body.
2. Printing ink (biological printing material) preparation
The printing ink can be purchased through commercial paths and can also be prepared according to actual needs, the printing material (printing ink) is prepared before printing, and the specific preparation process is as follows:
1) Preparation of printing ink for Main Material (bovine fibrinogen and thrombin)
0.02g of the powder of bovine fibrinogen stored in a refrigerator at-20 ℃ is taken out and dissolved in 500 μl of DMEM/F-12 HEPES culture solution, so as to ensure complete dissolution of DMEM in the culture solution and no precipitation.
The thrombin is firstly split-packed into a plurality of EP tubes by PBS, each tube contains 100U and is stored at the temperature of minus 20 ℃, only one tube is needed to be taken out for preparing a batch of materials, and the same DMEM/F-12 HEPES culture solution is used for diluting into a total mother solution of 20U/ml and 5ml, the mother solution is wrapped with tinfoil and is stored in a refrigerator at the temperature of 4 ℃ in a dark place, and one batch of mother solution is printed for a plurality of times. For each printing, a new EP tube was first filled with a single particle of anhydrous calcium chloride having a mass of about 0.12g, and 500. Mu.l of thrombin mother liquor was added for blowing until complete dissolution, and the solution was placed in a 37℃incubator for 5 minutes after completion of the preparation.
The final concentration used in this example was 20mg/ml fibrinogen, 10U/ml thrombin and 120mM calcium chloride.
2) Preparation of cells in printing ink
The cells used in the printing of this example were human bile duct epithelial progenitor cells (CP, cholangiocyte progenitor).
(1) hPSCs cell culture: and (5) taking a proper amount of hPSCs for resuscitating culture for alternative use. On the first day, multifunctional hepatocytes hPSCs were subjected to a liquid exchange procedure using a medium rich in activin A (100 ng/ml), bFGF (80 ng/ml), BMP-4 (10 ng/ml), LY294002 (10. Mu.M) and CHIR99021 (3. Mu.M), and incubated overnight at 37 ℃.
(2) Differentiation culture of hPSCs into DE: the next day, the culture broth was replaced with CDM-PVA supplemented with activin A (100 ng/ml), bFGF (80 ng/ml), BMP-4 (10 ng/ml) and LY294002 (10. Mu.M). Incubated overnight at 37 ℃. On the third day, the culture broth was replaced with a new RPMI/B27 culture broth supplemented with activin A (100 ng/ml) and bFGF (80 ng/ml).
(3) Differentiation of DE into FP cells: on days 4-6, the old broth was replaced with the newly prepared RPMI/B27 broth supplemented with activin A (50 ng/ml). On days 7,8, the medium was replaced with a new formulation of RPMI/B27 medium supplemented with activin A (50 ng/ml).
(4) Differentiation of FP cells into HB cells: on days 9-12, the medium was replaced with a freshly prepared RPMI/B27 medium containing SB-431542 (10. Mu.M) and BMP-4 (50 ng/ml). Differentiation of HB hepatic progenitors was detected by expression of HNF4A, AFP and TBX3 and flow analysis. Differentiation of FP cells into HB cells HB was achieved.
(5) Differentiation of HBs cells into CPs: on days 13-16, differentiation of biliary epithelial progenitor cells was examined by Sox9 expression using a freshly prepared RPMI/B27 medium containing FGF10 (50 ng/ml), activin a (50 ng/ml) and retinoid acid (3 μm) instead of medium. Ensuring differentiation of hepatic progenitors into biliary epithelial progenitors.
(6) Cells were rinsed with PBS, cell digests were added and stored at 37 ℃ for 20 minutes. Cells were separated from the bottom plate and collected using a pipette. Cells were transferred to a 15 ml tube, gently blown and resuspended 2-3 times, and the cells were separated into small clumps using a 1000 microliter pipette. Plates were rinsed with RPMI/B27 medium and transferred to 15 ml tubes. Centrifuge for 3 min at room temperature. The supernatant was aspirated and the cells resuspended at 6 ml RPMI/B27. Centrifuge for 3 min at room temperature and aspirate the supernatant. The cells were resuspended in a pre-prepared 50% matrigel containing EGF (20 ng/ml) and Rho kinase inhibitor Y-27632 (10 μm) and mixed well.
Counting by using a cell counting plate to obtain cell concentration and estimating total cell number, centrifuging again, taking out required cell number solution after counting, and adding 500 μl fibrinogen solution prepared before removing supernatant to obtain 4×10 concentration 6 cell/ml of fibrinogen solution containing cells.
3. Print settings
The injection and pressure driving of printing ink are carried out by using a baoding Shen Chen SPLab02 injection pump, and before each printing, the flow channel is injected by deionized water, so that the resistance can be reduced when materials are added, and the flow channel reaches a steady state as soon as possible. After the washing, the chips were connected with tubes of fibrinogen and thrombin, and liquid was introduced into them, and the total amount was set to 5. Mu.l/min, and 400. Mu.l, respectively, and the syringe pump was adjusted to allow the flow path to reach a steady state rapidly. When the pink liquid bead gel appears below the chip, the printer beam on the microfluidic chip spray head frame can be seen, and the distance between the spray head and the glass tube for winding is about 3-4mm.
The printer parameter part is adjusted to ensure that the tubular tissue without gaps can be stably printed.
4. Print product detection and parameter correction
And (3) using an optical microscope and an electronic scanning microscope to observe and detect the printed tubular structure, correcting printing parameters (the rotation rate of a winding rod, the injection rate and the translation speed of a microfluidic chip nozzle and the like), and printing again.
5. Printing finished product culture
The printed fibrin bile duct structure was placed in freshly prepared WE medium of EGF (20 ng/ml), with medium replaced every 2 days. Organoid tissue formed during 2-4 days of culture.
6. Cholangization detection of physicochemical property and biological property of tubular tissue
After the hollow fiber protein structure is cultured in the culture solution for a period of time, the hollow fiber protein structure is taken out for detection of mechanical properties and biological properties. Differentiation of bile duct epithelial-like cells was examined by CK7 expression, ensuring that it could be observed in > 75% of cells. The expression of CK19 is detected by immunofluorescence staining, and the growth condition of bile duct epithelial cells is characterized. Alkaline phosphatase staining performance and glutamyl transpeptidase activity, which are used to characterize bile duct epithelial cell function, were examined. The CK19 immunofluorescence staining chart (fig. 6) shows positive expression of CK19, which indicates that the growth state of bile duct epithelial cells is good, and a tubular structure is generated.
EXAMPLE 3 construction of tubular bronchus-like Structure
1. Print platform preparation
The printing platform with the stainless steel alloy frame structure mainly comprises a printing nozzle and a winding unit for tubular construction. The printing platform and the components thereof are designed in an autonomous drawing mode, and each component can be processed through enterprise customization or entrusting professional machining units.
The micro-fluidic chip spray head designed based on the micro-fluidic principle is applied to the embodiment, and PMMA material is applied to construct the micro-fluidic chip spray head with a single flow channel. The spray head can accurately control the flow of the solution.
The glass tube for winding used in this example has a diameter of about 1cm, which is similar to the diameter of a bronchus of a human body.
2. Printing ink (biological printing material) preparation
The printing ink can be purchased through commercial paths and can also be prepared according to actual needs, the tubular bronchus-like structure is required to be printed, and a printing material (printing ink) is prepared before printing, and the specific preparation process is as follows:
1) Preparation of printing ink for Main Material (alginic acid and gelatin)
Gelatin (Sigma-Aldrich, G1890) and sodium alginate (Sigma-Aldrich, A0682) were dissolved in 0.5% (w/v) sodium chloride solution to form a 15% gelatin solution and a 4% sodium alginate solution, respectively.
2) Preparation of cells in printing ink
The cells used in this example were human lung bronchial epithelial cells (Beas-2B) and human fetal lung fibroblasts (MRC-5).
Cell culture: the culture was performed using H-DMEM medium (Hyclone, SH 30022.01) (containing 10% FBS). When the cells were grown to confluence at about 80% of the bottom of the dish, they were digested with 0.25% pancreatin (TargetMol, T0517-50 mg) containing 0.04% edta, passaged at 1:6 ratio and the culture was changed every other day.
3. Print settings
600. Mu.L of gelatin solution and 400. Mu.L of sodium alginate solution were incubated at 37℃for 20 minutes, and gently mixed as a matrix material. Beas-2B and MRC-5 cells (cell density 6X 10) 5 And (3) per ml, in a ratio of 5:1).
The injection and pressure driving of printing ink are carried out by using a baoding Shen Chen SPLab02 injection pump, and before each printing, the flow channel is injected by deionized water, so that the resistance can be reduced when materials are added, and the flow channel reaches a steady state as soon as possible. After the washing is finished, the chip is connected with the mixed solution and is filled with the mixed solution, the total amount of the mixed solution is set to be 5 mu l/min, and the total amount of the mixed solution is set to be 400 mu l, so that the injection pump is regulated, and the flow channel is quickly stable. The distance between the nozzle and the glass tube for winding is about 3-4mm.
The printer parameter part is adjusted to ensure that the tubular tissue without gaps can be stably printed.
4. Print product detection and parameter correction
And (3) using an optical microscope and an electronic scanning microscope to observe and detect the printed tubular structure, correcting printing parameters (the rotation rate of a winding rod, the injection rate and the translation speed of a microfluidic chip nozzle and the like), and printing again.
5. Printing finished product culture
The printed bronchus-like structure was placed in 5% CO 2 Culturing in a 37 ℃ incubator, and replacing the culture medium every 1-2 days in freshly prepared H-DMEM medium (containing 10% FBS).
6. Bronchioloid detection of physical and chemical properties and biological properties of tubular tissue
After the bronchus-like hollow structure is cultured in the culture solution for a period of time, the bronchus-like hollow structure is taken out for detection of mechanical properties and biological properties. After 7 days of growth after construction of the bronchus-like structure, HE staining showed cell connective growth; the broad spectrum CK and Vimentin staining both had positive results, indicating better cell activity.
While the invention has been described in detail in the foregoing general description and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.
Claims (3)
1. The construction method of the tubular vascular structure is characterized by comprising the following steps:
1) 0.02g of bovine fibrinogen was dissolved in 500. Mu.l of DMEM/F-12HEPES medium to obtain a fibrinogen solution;
2) Human umbilical vein endothelial cells HUVEC were cultured in vitro with EBM-2Endothelial Growth Basal Medium and passaged, cultured until the fourth generation before printing, cells were rinsed with PBS, then Trypsin-EDTA was added to the flask, digested in an incubator at 37℃for 2 minutes, and then the digestion was stopped by adding EBM broth; centrifuging in a centrifuge, removing supernatant, re-suspending cells with culture solution, counting, centrifuging again, removing supernatant, and adding fibrinogen solution of step 1) to cell sediment to obtain 4×10 6 cell/ml of a cell-containing fibrinogen solution as printing reagent 1;
3) Preparing 20U/ml thrombin mother liquor by using DMEM/F-12HEPES culture solution; before printing, 500 μl of thrombin mother liquor is added into 0.12g of anhydrous calcium chloride, dissolved and placed into a 37 ℃ incubator for 5 minutes to be incubated as a printing reagent 2;
4) And (3) respectively connecting the printing reagents 1 and 2 with different spray heads of the biological printer, printing on a winding rod together to form a seamless tubular tissue, and removing the winding rod to obtain the hollow tubular vascular-like structure.
2. The method according to claim 1, wherein the distance between the spray head and the winding rod in step 4) is 3-4mm; and/or
The rotation speed of the motor driver for driving the winding rod to rotate is 0-10000cts/s, and the rotation speed of the motor driver for driving the printing spray head to translate is 0-10000cts/s.
3. A tubular vascular-like structure constructed according to the method of claim 1 or 2.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311449958.4A CN117717434A (en) | 2019-06-24 | 2019-06-24 | Tubular bile duct-like structure and construction method thereof |
| CN201910549415.7A CN112206074B (en) | 2019-06-24 | 2019-06-24 | Tubular vascular-like structure and construction method thereof |
| CN202311450029.5A CN117679205A (en) | 2019-06-24 | 2019-06-24 | Tubular bronchus-like structure and method for constructing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910549415.7A CN112206074B (en) | 2019-06-24 | 2019-06-24 | Tubular vascular-like structure and construction method thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311450029.5A Division CN117679205A (en) | 2019-06-24 | 2019-06-24 | Tubular bronchus-like structure and method for constructing same |
| CN202311449958.4A Division CN117717434A (en) | 2019-06-24 | 2019-06-24 | Tubular bile duct-like structure and construction method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112206074A CN112206074A (en) | 2021-01-12 |
| CN112206074B true CN112206074B (en) | 2024-01-02 |
Family
ID=74047014
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311450029.5A Pending CN117679205A (en) | 2019-06-24 | 2019-06-24 | Tubular bronchus-like structure and method for constructing same |
| CN202311449958.4A Pending CN117717434A (en) | 2019-06-24 | 2019-06-24 | Tubular bile duct-like structure and construction method thereof |
| CN201910549415.7A Active CN112206074B (en) | 2019-06-24 | 2019-06-24 | Tubular vascular-like structure and construction method thereof |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311450029.5A Pending CN117679205A (en) | 2019-06-24 | 2019-06-24 | Tubular bronchus-like structure and method for constructing same |
| CN202311449958.4A Pending CN117717434A (en) | 2019-06-24 | 2019-06-24 | Tubular bile duct-like structure and construction method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN117679205A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112843334B (en) * | 2021-01-13 | 2022-07-08 | 东华大学 | Bionic trachea constructed by three-dimensional printing composite aerogel and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104490489A (en) * | 2014-12-02 | 2015-04-08 | 淮安皓运生物科技有限公司 | Method for preparing tissue engineering blood vessel based on 3D bioprinting technology |
| CN105983134A (en) * | 2015-03-05 | 2016-10-05 | 刘畅 | Artificial blood vessel and preparation method thereof |
| CN106139251A (en) * | 2015-04-02 | 2016-11-23 | 清华大学 | A kind of preparation method and applications of engineering three-dimensional tissue structures body |
| CN106635954A (en) * | 2016-10-12 | 2017-05-10 | 武汉枫霖科技有限公司 | 3D biological printing based method for constructing three-dimensional vascular tissue |
| CN106916781A (en) * | 2015-12-25 | 2017-07-04 | 清华大学 | A kind of construction method of external 3 D human body hepatic tissue and its application |
| CN107164318A (en) * | 2017-07-19 | 2017-09-15 | 叶川 | Method and hollow form vascularised heart based on 3D biometric print technique construction hollow form vascularised hearts |
| CN108525021A (en) * | 2018-04-17 | 2018-09-14 | 山西医科大学 | Contain blood vessel and hair follicle structure organization engineering skin and preparation method thereof based on 3D printing |
-
2019
- 2019-06-24 CN CN202311450029.5A patent/CN117679205A/en active Pending
- 2019-06-24 CN CN202311449958.4A patent/CN117717434A/en active Pending
- 2019-06-24 CN CN201910549415.7A patent/CN112206074B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104490489A (en) * | 2014-12-02 | 2015-04-08 | 淮安皓运生物科技有限公司 | Method for preparing tissue engineering blood vessel based on 3D bioprinting technology |
| CN105983134A (en) * | 2015-03-05 | 2016-10-05 | 刘畅 | Artificial blood vessel and preparation method thereof |
| CN106139251A (en) * | 2015-04-02 | 2016-11-23 | 清华大学 | A kind of preparation method and applications of engineering three-dimensional tissue structures body |
| CN106916781A (en) * | 2015-12-25 | 2017-07-04 | 清华大学 | A kind of construction method of external 3 D human body hepatic tissue and its application |
| CN106635954A (en) * | 2016-10-12 | 2017-05-10 | 武汉枫霖科技有限公司 | 3D biological printing based method for constructing three-dimensional vascular tissue |
| CN107164318A (en) * | 2017-07-19 | 2017-09-15 | 叶川 | Method and hollow form vascularised heart based on 3D biometric print technique construction hollow form vascularised hearts |
| CN108525021A (en) * | 2018-04-17 | 2018-09-14 | 山西医科大学 | Contain blood vessel and hair follicle structure organization engineering skin and preparation method thereof based on 3D printing |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117717434A (en) | 2024-03-19 |
| CN117679205A (en) | 2024-03-12 |
| CN112206074A (en) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han et al. | Effect of pore size on cell behavior using melt electrowritten scaffolds | |
| US20230320837A1 (en) | Multilayered Vascular Tubes | |
| Skardal et al. | Photocrosslinkable hyaluronan-gelatin hydrogels for two-step bioprinting | |
| Duarte Campos et al. | The stiffness and structure of three-dimensional printed hydrogels direct the differentiation of mesenchymal stromal cells toward adipogenic and osteogenic lineages | |
| Liao et al. | Stem cells and biomimetic materials strategies for tissue engineering | |
| Burdick et al. | Engineered microenvironments for controlled stem cell differentiation | |
| CN110302428B (en) | Cartilage-bone-marrow composite tissue structure and method based on living cell 3D printing | |
| Lan et al. | Bioprinting of human nasoseptal chondrocytes‐laden collagen hydrogel for cartilage tissue engineering | |
| Park et al. | 3D bioprinting of a trachea-mimetic cellular construct of a clinically relevant size | |
| Xu et al. | The application of 3D bioprinting in urological diseases | |
| Ke et al. | Current challenges of bioprinted tissues toward clinical translation | |
| Oseni et al. | Cartilage tissue engineering: the application of nanomaterials and stem cell technology | |
| Chae et al. | 3D bioprinting adipose tissue for breast reconstruction | |
| CN112206074B (en) | Tubular vascular-like structure and construction method thereof | |
| Bayir et al. | Bioreactors in tissue engineering: mimicking the microenvironment | |
| Wang et al. | Microscale tissue engineering of liver lobule models: advancements and applications | |
| Shu et al. | Three-dimensional printing and decellularized-extracellular-matrix based methods for advances in artificial blood vessel fabrication: a review | |
| Navarro et al. | Bioinks for three-dimensional printing in regenerative medicine | |
| WO2022083037A1 (en) | Bionic artificial liver tissue, preparation method therefor and application thereof | |
| Liu et al. | A novel method for generating 3D constructs with branched vascular networks using multi-materials bioprinting and direct surgical anastomosis | |
| Zhong et al. | A facile approach for engineering tissue constructs with vessel-like channels by cell-laden hydrogel fibers | |
| Liang et al. | New insights and advanced strategies for in vitro construction of vascularized tissue engineering | |
| Kengla et al. | Bioprinting of organoids | |
| CN114381419B (en) | Bionic artificial liver tissue and preparation method and application thereof | |
| CN114377209B (en) | Artificial liver structure containing bile duct and liver tissue and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |